April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
The Fc fragments of Bevacizumab or IVIG suppress choroidal neovascularization
Author Affiliations & Notes
  • shengjian li
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Nagaraj Kerur
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Sasha Bogdanovich
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Reo Yasuma
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Younghee Kim
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Takeshi Mizutani
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Ana Bastos-Carvalho
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Jayakrishna Ambati
    Department of Ophthalmology and Visual Sciences, University of Kentucky, lexington, KY
  • Footnotes
    Commercial Relationships shengjian li, None; Nagaraj Kerur, None; Sasha Bogdanovich, None; Reo Yasuma, None; Younghee Kim, None; Takeshi Mizutani, None; Ana Bastos-Carvalho, None; Jayakrishna Ambati, University of Kentucky (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1191. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      shengjian li, Nagaraj Kerur, Sasha Bogdanovich, Reo Yasuma, Younghee Kim, Takeshi Mizutani, Ana Bastos-Carvalho, Jayakrishna Ambati; The Fc fragments of Bevacizumab or IVIG suppress choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1191.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Choroidal neovascularization (CNV) in humans is often treated with full-length bevacizuman or the Fab fragment ranibizumab. Although bevacizumab does not bind or block mouse VEGF it has been reported to suppress mouse CNV. We tested the hypothesis that this anti-angiogenic effect of bevacizumab in mice was due not to mouse VEGF targeting but due to a novel effect of its Fc fragment. We tested Fab and Fc fragments of bevacizumab as well as of those of “intravenous human immunoglobulin” (IVIG), a widely used clinical therapeutic in mouse CNV.

Methods: Commercially supplied bevacizumab or IVIG was digested with Papain, and the further purified Fab and Fc fragments were tested in the laser injury CNV model in WT and Fcgr1-deficient mice. CNV size was quantified by volumetric assessment.

Results: Bevacizumab-Fc and IVIG-Fc suppressed CNV in WT mice, whereas bevacizumab-Fab and IVIG-Fab did not do so. Bevacizumab-Fc and IVIG-Fc did not suppress CNV in Fcgr1-deficient mice.

Conclusions: These data identify a novel anti-angiogenic function of the Fc fragment of human immunoglobulin-containing therapeutic preparations and clarify earlier puzzling data of the bioactivity of bevacizumab in mice.

Keywords: 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×